Many Oncologists Favor Consolidation Immunotherapy Following Chemoradiation for Stage III NSCLC
November 21st 2020During a Targeted Oncology Case Based Peer Perspectives event, John Heymach, MD, PhD, professor and Chair, David Bruton Jr Chair in Cancer Research. Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discussed the guidelines and therapeutic option for stage III non–small cell lung cancer, based on a case of a 66-year-old patient.
Emerging Data May Provide More Options for Systemic Treatment of Basal Cell Carcinoma, Says In
November 12th 2020During a Targeted Oncology Case Based Peer Perspective event, Gino K. In, MD, MPH, assessed the risk status of an 88-year-old patient with basal cell carcinoma and discussed treatment options.
Pennell Considers Treatments in Front- and Later-Line Settings for EGFR+ NSCLC
November 8th 2020In the treatment of EGFR-mutant non–small cell lung cancer, oncologists face multiple challenges with prescribing medications to patients. During a Targeted Oncology Case Based Peer Perspective event, Nathan Pennell, MD, PhD, discussed these challenges as well as potential treatment approaches with a group of peers.
Heymach Discusses MET Exon 14 Skipping Mutations in NSCLC
November 3rd 2020During a Targeted Oncology Case Based Peer Perspective event, John V. Heymach, MD, PhD, discussed the testing methods for non–small cell lung cancer with MET exon 14 skipping mutations. The discussion was based on the case of a 48-year-old woman.
Brander Details Different Therapies and Modalities for Treatment of CLL in the Second Line
October 29th 2020During a Targeted Oncology Case Based Peer Perspectives event, Danielle Brander, MD, assistant professor of Medicine at Duke Cancer Institute in Durham, NC, discussed options for treating a 53-year-old female patients with chronic lymphocytic leukemia.